Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate to Prevent Post-ERCP Pancreatitis: a Multicentre, Non-inferiority, Double-blind, Randomised Trial
Overview
- Phase
- Not Applicable
- Intervention
- Indomethacin 100 MG
- Conditions
- Post-ERCP Acute Pancreatitis
- Sponsor
- Air Force Military Medical University, China
- Enrollment
- 2700
- Locations
- 4
- Primary Endpoint
- Rate of post-ERCP Pancreatitis
- Last Updated
- 5 years ago
Overview
Brief Summary
Patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) are at risk for post-ERCP pancreatitis (PEP), which is associated with adverse outcomes. Combination prophylaxis strategies are increasingly investigated to prevent PEP more effectively, and studies have confirmed the benefits. Two randomized controlled trials revealed that combination prophylaxis with rectal NSAIDs and sublingual nitrate has reduced PEP rates to 5.6%-6.7% in average-risk patients. However, there was concern regarding the safety of sublingual nitrate with reports of significant increasing the risk of hypotesion (rate of 54.9%) and headache (rate of 4.1%) as compared with placebo.
As a safety drug, rectal administration of one dose NSAIDs is recommended as basic chemoprophylaxis in common or high-risk patients in guidelines. Results from previous studies showed rectal administration of NSAIDs significantly reduced PEP rate to 4-5.3% in average-risk patients. Although the difference in demographics, study design and outcomes definition, evidence was obtained that rectal NSAIDS was associated with similar PEP rate as combination prophylaxis with rectal NSAIDs and sublingual nitrate. However, evidence is lacking from large, randomized clinical trials indicating that efficiency of PEP prevention with rectal NSAIDs alone is not inferior to with combination prophylaxis. The investigators conduct this trial to investigate the hypothesis that rectal NSAIDs alone is non-inferior to the combination prophylaxis in terms of PEP prevention, but with reduce side effect.
Investigators
Yanglin Pan
Associated professor
Air Force Military Medical University, China
Eligibility Criteria
Inclusion Criteria
- •Patients (age, 18-80 y) with native papilla planned for diagnostic or therapeutic ERCP were eligible for enrollment in the study.
Exclusion Criteria
- •contraindications to ERCP;
- •allergy to nitrates or NSAIDs;
- •currently on nitrate medication;
- •receiving NSAIDs within 7 days;
- •not suitable for indomethacin eg, gastrointestinal hemorrhage within the past 4 weeks, renal dysfunction (creatinine level \>1.4 mg/dL) or the presence of coagulopathy before the procedure (international normalized ratio \> 1.5);
- •acute pancreatitis within 3 days;
- •pregnant or breastfeeding women;
- •unwilling or inability to provide consent.
Arms & Interventions
Rectal indomethacin and sublingual placebo
All patients without contraindications should receive sublingual placebo within 5 min before ERCP. All patients without contraindications should receive rectal indomethacin within 30 min before ERCP.
Intervention: Indomethacin 100 MG
Rectal indomethacin and sublingual nitrate
All patients without contraindications should receive sublingual isosorbide dinitrate within 5 min before ERCP. All patients without contraindications should receive rectal indomethacin within 30 min before ERCP.
Intervention: Isosorbide Dinitrate 5 MG
Rectal indomethacin and sublingual nitrate
All patients without contraindications should receive sublingual isosorbide dinitrate within 5 min before ERCP. All patients without contraindications should receive rectal indomethacin within 30 min before ERCP.
Intervention: Indomethacin 100 MG
Rectal indomethacin and sublingual placebo
All patients without contraindications should receive sublingual placebo within 5 min before ERCP. All patients without contraindications should receive rectal indomethacin within 30 min before ERCP.
Intervention: Sublingual Placebo
Rectal placebo and sublingual nitrate
All patients without contraindications should receive sublingual isosorbide dinitrate within 5 min before ERCP. All patients without contraindications should receive rectal placebo within 30 min before ERCP.
Intervention: Isosorbide Dinitrate 5 MG
Rectal placebo and sublingual nitrate
All patients without contraindications should receive sublingual isosorbide dinitrate within 5 min before ERCP. All patients without contraindications should receive rectal placebo within 30 min before ERCP.
Intervention: Rectal placebo
Rectal placebo and sublingual placebo
All patients without contraindications should receive sublingual placebo within 5 min before ERCP. All patients without contraindications should receive rectal placebo within 30 min before ERCP.
Intervention: Sublingual Placebo
Rectal placebo and sublingual placebo
All patients without contraindications should receive sublingual placebo within 5 min before ERCP. All patients without contraindications should receive rectal placebo within 30 min before ERCP.
Intervention: Rectal placebo
Outcomes
Primary Outcomes
Rate of post-ERCP Pancreatitis
Time Frame: 14 days
The diagnosis of PEP was established if there was new onset of upper abdominal pain associated with an increased amylase or lipase level of at least 3 times the upper limit of normal range at 24 hours after the procedure, and hospitalization for at least 2 nights. Doctors are advised to use cross-sectional imaging to identify ambiguous PEP.
Secondary Outcomes
- Other adverse events(14 days)
- Rate of moderate to severe PEP(14 days)